DorsaVi raises A$3 million for humanoid robotics and RRAM chips

By Splitfeed EditorialLast updated Oct 6, 2026, 12:10 UTC

On 5 October 2026, Australian wearable motion sensor company DorsaVi completed a share placement raising A$3 million, equivalent to roughly US$2.09 million. The capital is earmarked for two linked programs: embedding DorsaVi's existing sensor technology into humanoid robot platforms, and developing resistive RAM, or RRAM, chips. The company frames this as an extension of its core business, moving sensor hardware from human bodies into robotic ones.

The raise is modest in absolute terms but signals a strategic pivot for a company whose revenue has traditionally come from clinical and occupational health applications of motion capture. RRAM is a category of non-volatile memory that proponents argue is faster and more energy-efficient than conventional flash storage, making it a candidate for edge computing in autonomous systems. Whether a small-cap wearables firm can execute credibly across both humanoid robotics integration and chip development is the central question, because those are distinct engineering disciplines requiring different expertise and partnerships that DorsaVi has not yet publicly detailed.

None of the three camps, Pro-AI, Anti-AI, or Middle Ground, had published reactions to this story at the time of writing. Pro-AI observers would typically welcome a company redirecting sensor expertise toward physical AI platforms, treating it as evidence of the robotics supply chain broadening beyond large incumbents. Anti-AI commentators would likely question whether the announcement reflects genuine technical progress or is primarily a capital-raising narrative designed to attract investor interest in a hot sector. Middle Ground voices would probably focus on the execution risk, noting that A$3 million is a thin budget for simultaneous hardware development across two technically demanding fronts.

The arguments on all sides will sharpen once DorsaVi discloses partnership agreements with humanoid robot manufacturers, any licensing or fabrication arrangements for the RRAM program, or follow-on funding rounds that would indicate whether institutional investors find the dual strategy credible.